RedHill Biopharma

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RedHill Biopharma Ltd's (NASDAQ: RDHL) opaganib (ABC294640), an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability.  The Company says that based on the new and.

RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants

- Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collaborating center     - Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations and remain effective against Omicron sub-variants BA.2, XE and other emerging and future variants - Previously reported phase 2/3 clinical data showed reduced mortality in key subpopulations, improved viral RNA clearance, and faster time to recovery for moderate to severe hospitalized patients treated with opaganib - Regulatory submissions and discussions in the U.S., Europe, UK and additional countries are progressing regarding confirmatory data requirements and pathways to potential approval TEL AVIV, Israel and RALEIGH, N.C., April 11, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collaborating center Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected to act independently of viral spike protein mutations and remain effective against Omicron sub-variants BA.2, XE and other emerging and future variants Previously reported phase 2/3 clinical data showed reduced mortality in key subpopulations, improved viral RNA clearance, and faster time to recovery for moderate to severe hospitalized patients treated with opaganib Regulatory submissions and discussions in the U.S., Europe, UK and additional countries are progressing regarding confirmatory data requirements and pathways to potential approval TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / April 11, 2022 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640)[1], a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2021 Results - Earnings Call Transcript

TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

RedHill Biopharma Ltd (NASDAQ: RDHL) has entered into an exclusive license agreement with Kukbo Co Ltd for oral opaganib to treat COVID-19 in South Korea.  Under the terms of the license agreement, which follows the previously announced strategic investment .

RedHill, Kukbo Ink Oral Opaganib Licensing Pact For COVID-19 In South Korea

TEL-AVIV, Israel, and RALEIGH, N.C. , March 15, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill and Kukbo Enter Oral Opaganib License for COVID-19 in South Korea

TEL AVIV, Israel and RALEIGH, NC , March 10, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results and operational highlights on Thursday, March 17, 2022.

RedHill Biopharma to Host Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights Webcast on March 17, 2022

TEL AVIV, Israel and RALEIGH, N.C., March 1, 2022 /PRNewswire/ --  RedHill Biopharma Ltd.

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

TEL AVIV, Israel and RALEIGH, N.C., Feb. 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma Announces Record Quarterly Revenues and First Commercial Operations Breakeven

TEL AVIV, Israel and RALEIGH, N.C.  , Feb. 7, 2022 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

RedHill Biopharma Ltd (NASDAQ: RDHL) announced new data from a prespecified analysis of all oral opaganib's Phase 2/3 study patients in COVID-19 patients. The data demonstrated that opaganib improved the median time to viral RNA clearance by at least four days.

RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance

ReTo Eco-Solutions

Splash Beverage Group

Popular penny stocks on Reddit today. Are they a buy?

3 Top Penny Stocks To Watch As Redditors Buy The Dip

- In a prespecified analysis of all Phase 2/3 study patients with positive PCR at screening, opaganib improved the median time to viral RNA clearance by at least 4 days; Median of 10 days for viral clearance in the opaganib arm vs. clearance median not reached by end of 14-day treatment in placebo arm (Hazard Ratio 1.34; nominal p-value=0.043, N=437/463) - Opaganib is the first oral novel drug candidate to show improved viral RNA clearance in patients with severe COVID-19 pneumonia; Provides clinical evidence supporting opaganib's potential antiviral activity - Results achieved in a severely ill hospitalized patient population with a median of 11-days from onset of symptoms - a patient population much further advanced than mild-moderate outpatients with less than 5 days from symptom onset, for which oral anti-viral medications have recently been approved - Results add to opaganib's 62% reduction in mortality seen in a post-hoc analysis of the Phase 2/3 study and are being provided to regulators as part of ongoing discussions on potential pathways to approval in multiple countries TEL AVIV, Israel and RALEIGH, N.C.

RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

RALEIGH, N.C. and TEL-AVIV, Israel, Jan. 6, 2022 /PRNewswire/ --  RedHill Biopharma Ltd.

RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates

RDHL has had many avatars, and the latest one has taken the stock down considerably.

RedHill Biopharma: Looking At An Unexciting Dead-End

RALEIGH, NC and TEL-AVIV, ISRAEL / ACCESSWIRE / December 15, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that members of its board of directors and senior management, including the Company's Chairman & CEO, Mr.

RedHill Announces Additional Insider Buying

RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 15, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma Announces Additional Insider Buying

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced the publication of a new study revealing concerning rates of widespread, physician-directed prescribing of clarithromycin-based regimens for H. pylori infection despite rising rates of antibiotic resistance and prior patient macrolide use.

RedHill Biopharma's Talicia Recommended For H. Pylori Infection

The stock price of RedHill Biopharma Ltd (NASDAQ: RDHL) increased by over 4% during intraday trading today. This is why it happened.

RedHill Biopharma Stock (RDHL): Why The Price Increased Today

RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication Despite increasing resistance to, and suboptimal H.

RedHill Biopharma Ltd Announces Concerning Clarithromycin Rx Rates for H. pylori

RALEIGH, N.C. and TEL-AVIV, Israel, Dec. 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

RedHill Biopharma: Concerning Rates of Clarithromycin Prescribing for H. pylori, Despite Increasing Antibiotic Resistance, Uncovered in New Digestive Diseases & Sciences Publication

RedHill Biopharma Ltd (NASDAQ:RDHL) has said that because its opaganib treatment's proposed mechanism of action is not impacted by spike protein mutations, the drug is expected to be unaffected by mutations associated with the  Omicron and other known coronavirus (COVID-19) variants of concern.  The company noted that increased hospitalizations in South Africa due to Omicron highlight the urgent need for drugs aimed at moderately severe COVID-19 patients with pneumonia requiring hospital treatment.

RedHill Biopharma says opaganib proposed mechanism of action not impacted by spike protein mutations, including Omicron mutations; provides update on regulatory submissions for opaganib

Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of concern Regulatory update Opaganib global Phase 2/3 data packages submitted to European EMA, with initial feedback expected by end of year, to the U.S. FDA with initial feedback expected in January, and to the UK MHRA, with other countries lined up A number of pending grant applications in the U.S. and abroad with both government bodies and non-government entities Opaganib designed for underserved hospitalized patient population with advanced disease; Opaganib treatment initiated a median of 11 days from symptom onset in the Phase 2/3 global study, compared to the limited 3-5-day from symptom onset scope of the Pfizer & Merck pills RHB-107, RedHill's other oral COVID-19 drug candidate, expected to deliver top-line data in Q1/2022 from Part A of its Phase 2/3 study in non-hospitalized patients in the U.S. and South Africa; RHB-107 also not expected to be impacted by spike protein mutations TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / December 6, 2021 / RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that because opaganib's [1] proposed mechanism of action is not impacted by spike protein mutations, opaganib is expected to be unaffected by mutations associated with Omicron and other known variants of concern.

RedHill Biopharma Ltd - Opaganib MoA Not Impacted by Omicron Mutations

Unique Mode of Action Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron SARS-CoV-2 variant, as well as other variants of concern Regulatory update Opaganib global Phase 2/3 data packages submitted to European EMA, with initial feedback expected by end of year, to the U.S. FDA with initial feedback expected in January, and to the UK MHRA, with other countries lined up A number of pending grant applications in the U.S. and abroad with both government bodies and non-government entities Opaganib designed for underserved hospitalized patient population with advanced disease; Opaganib treatment initiated a median of 11 days from symptom onset in the Phase 2/3 global study, compared to the limited 3-5-day from symptom onset scope of the Pfizer & Merck pills RHB-107, RedHill's other oral COVID-19 drug candidate, expected to deliver top-line data in Q1/2022 from Part A of its Phase 2/3 study in non-hospitalized patients in the U.S. and South Africa; RHB-107 also not expected to be impacted by spike protein mutations TEL AVIV, Israel and RALEIGH, N.C., Dec. 6, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

News for RedHill Biopharma Stock (RDHL)